RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Dapagliflozin Does Not Impact Renal Function in Patients with Type 2 Diabetes
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 16
SP 21
OP 21
DO 10.1177/155989771216009
UL http://mdc.sagepub.com/content/12/16/21.1.abstract
AB Treatment with dapagliflozin (DAPA) is not associated with an increased risk of acute renal toxicity or long-term deterioration of renal function in patients with type 2 diabetes mellitus (T2DM) according to the results of a pooled analysis of 12 studies [NCT00263276; NCT00972244; NCT00528372; NCT00736879; NCT00528879; NCT00855166; NCT00357370; NCT00680745; NCT00683878; NCT00673231; NCT00643851; NCT00859898].